JP2019527555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527555A5 JP2019527555A5 JP2019505220A JP2019505220A JP2019527555A5 JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5 JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019505220 A JP2019505220 A JP 2019505220A JP 2019527555 A5 JP2019527555 A5 JP 2019527555A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- amino acids
- polypeptide chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 254
- 150000001413 amino acids Chemical class 0.000 claims 125
- 229920001184 polypeptide Polymers 0.000 claims 110
- 102000004196 processed proteins & peptides Human genes 0.000 claims 110
- 108090000765 processed proteins & peptides Proteins 0.000 claims 110
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 239000013604 expression vector Substances 0.000 claims 9
- 238000003259 recombinant expression Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021199878A JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| US62/369,883 | 2016-08-02 | ||
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Division JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527555A JP2019527555A (ja) | 2019-10-03 |
| JP2019527555A5 true JP2019527555A5 (enExample) | 2020-09-10 |
| JP6993402B2 JP6993402B2 (ja) | 2022-02-03 |
Family
ID=59564253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505220A Active JP6993402B2 (ja) | 2016-08-02 | 2017-07-31 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021199878A Active JP7413338B2 (ja) | 2016-08-02 | 2021-12-09 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2023221526A Active JP7649370B2 (ja) | 2016-08-02 | 2023-12-27 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
| JP2025036871A Pending JP2025090690A (ja) | 2016-08-02 | 2025-03-07 | 抗ｋｒａｓ－ｇ１２ｄ ｔ細胞受容体 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (enExample) |
| EP (2) | EP3494133B1 (enExample) |
| JP (4) | JP6993402B2 (enExample) |
| KR (1) | KR102527052B1 (enExample) |
| CN (2) | CN118063591A (enExample) |
| AU (3) | AU2017306038B2 (enExample) |
| CY (1) | CY1125601T1 (enExample) |
| DK (1) | DK3494133T3 (enExample) |
| ES (1) | ES2928051T3 (enExample) |
| HR (1) | HRP20221183T1 (enExample) |
| HU (1) | HUE060121T2 (enExample) |
| IL (2) | IL301894B2 (enExample) |
| LT (1) | LT3494133T (enExample) |
| PL (1) | PL3494133T3 (enExample) |
| PT (1) | PT3494133T (enExample) |
| RS (1) | RS63615B1 (enExample) |
| SG (2) | SG11201900654QA (enExample) |
| SI (1) | SI3494133T1 (enExample) |
| SM (1) | SMT202200379T1 (enExample) |
| WO (1) | WO2018026691A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900654QA (en) * | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| AU2018335274B2 (en) | 2017-09-20 | 2025-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted T cell receptors against mutated RAS |
| US12227554B2 (en) | 2017-10-05 | 2025-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| SG11202012653XA (en) * | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| CA3127673A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| GB2613715B (en) | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| EP3786178A1 (en) | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| JP7857860B2 (ja) * | 2019-11-05 | 2026-05-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｈｌａ拘束性ｈｏｒｍａｄ１ ｔ細胞受容体およびその使用 |
| JP2023507432A (ja) | 2019-12-20 | 2023-02-22 | インスティル バイオ （ユーケイ） リミテッド | 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用 |
| EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION |
| CA3168015A1 (en) * | 2020-02-12 | 2021-08-19 | Noam LEVIN | Hla class i-restricted t cell receptors against ras with g12d mutation |
| MX2022009825A (es) * | 2020-02-14 | 2022-10-13 | Us Health | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. |
| US20230159614A1 (en) * | 2020-02-26 | 2023-05-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
| EP4159768A4 (en) * | 2020-05-25 | 2024-11-20 | Bristar Immunotech Limited | Enhanced synthetic t-cell receptor and antigen receptor |
| CA3185241A1 (en) | 2020-07-13 | 2022-01-20 | Noam LEVIN | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| JP7829242B2 (ja) * | 2020-11-20 | 2026-03-13 | シンク・セラピューティクス・インコーポレイテッド | 最適化ペプチドワクチンの組成物および方法 |
| EP4251177A4 (en) * | 2020-11-25 | 2025-01-08 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| JP2026501145A (ja) * | 2022-12-13 | 2026-01-14 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
| WO2025259799A2 (en) * | 2024-06-12 | 2025-12-18 | Biontech Us Inc. | T cell receptor compositions and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| CA2674445C (en) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| US20140137274A1 (en) * | 2011-11-30 | 2014-05-15 | Lsip, Llc | Induced malignant stem cells |
| AU2014276440A1 (en) * | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| SG10201913978RA (en) | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| SG11201900654QA (en) * | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
| AU2024309123A1 (en) | 2023-06-28 | 2026-01-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 EP EP22182473.3A patent/EP4159751B1/en active Active
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2022
- 2022-09-29 CY CY20221100645T patent/CY1125601T1/el unknown
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
-
2026
- 2026-01-15 AU AU2026200276A patent/AU2026200276A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221183T1 (hr) | T-stanični receptori anti-kras-g12d | |
| JP2020534828A5 (enExample) | ||
| Walker et al. | Yeast eIF4B binds to the head of the 40S ribosomal subunit and promotes mRNA recruitment through its N-terminal and internal repeat domains | |
| Mo et al. | Targeting Ubc9 for cancer therapy | |
| Fournier et al. | Recruitment of RED-SMU1 complex by Influenza A Virus RNA polymerase to control Viral mRNA splicing | |
| CN100400657C (zh) | 磷酸激酶及其应用 | |
| JP2011188853A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| JP2018141797A5 (enExample) | ||
| Akiyama et al. | cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p | |
| Xu et al. | Sug1 modulates yeast transcription activation by Cdc68 | |
| Kabala et al. | Defining the impact on yeast ATP synthase of two pathogenic human mitochondrial DNA mutations, T9185C and T9191C | |
| Yan et al. | SUMOylation of W or1 by a novel SUMO E 3 ligase controls cell fate in C andida albicans | |
| Camier et al. | Visualization of ribonucleotide reductase catalytic oxidation establishes thioredoxins as its major reductants in yeast | |
| Auvray et al. | HOXC4 homeoprotein efficiently expands human hematopoietic stem cells and triggers similar molecular alterations as HOXB4 | |
| Zaccheo et al. | Kinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residues | |
| JP2020127419A5 (enExample) | ||
| CN104193826B (zh) | 一种融合多肽及其在制备抗肿瘤药物中的应用 | |
| CN103255113B (zh) | 一种发形霞水母过氧化物还原酶及其编码基因与应用 | |
| CA3213057A1 (en) | Use of adnf polypeptides in therapy | |
| Kitamura et al. | Fission yeast Ubr1 ubiquitin ligase influences the oxidative stress response via degradation of active Pap1 bZIP transcription factor in the nucleus | |
| CN103665141B (zh) | 与艰难梭菌细胞毒素b相互作用的蛋白 | |
| Murphy et al. | Identification of amdX, a new Cys‐2–His‐2 (C2H2) zinc‐finger gene involved in the regulation of the amdS gene of Aspergillus nidulans | |
| CN107164474B (zh) | 一种检测calr基因2型突变的引物组合物及试剂盒 | |
| Yang et al. | Ubl4b, an X-derived retrogene, is specifically expressed in post-meiotic germ cells in mammals |